Start of Phase I Study for Intranasal Pandemic Influenza Vaccin... ( VIENNA Austria July 8 /- Avir Gre...)

Start of Phase I Study for Intranasal Pandemic Influenza Vaccine deltaFLU

Date:7/8/2008

VIENNA, Austria, July 8 /PRNewswire/ -- Avir Green Hills Biotechnology starts a clinical phase I study with its intranasal vaccine deltaFLU against pandemic influenza. This novel generation of a live-attenuated vaccine based on the deletion of the NS1 gene has shown superior preclinical data. In taking this step, the Viennese biotech company sets yet another milestone in the development of effective and safe vaccines.

Aim of Phase I Study

The randomized, double-blind phase I study of the pandemic vaccine deltaFLU will be run at the Department of Clinical Pharmacology, Medical University of Vienna. The aim of phase I study is to analyze the safety and efficacy of the vaccine in healthy volunteers.

Preclinical Data, Pandemic Vaccine

"Our vaccine lacks the pathogenicity factor NS1. Due to this deletion, the vaccine is likely to show a superior safety profile. We are confident that the pandemic deltaFLU vaccine will be tolerated even at high doses," comments Thomas Muster, founder and CEO/CSO of Avir Green Hills Biotechnology.

Outstanding preclinical data show an excellent immune response even against distantly related pandemic H5 strains (cross-protection). Moreover, a long lasting immune response - an important prerequisite for an effective vaccine - was observed.

"We are very pleased about the success of our vaccine in the preclinical studies. The data are superb and exceed our highest expectations," reports Andrej Egorov, who is Vice President for Research at Avir Green Hills Biotechnology and one of the leading experts in the field of live attenuated influenza vaccines.

The novel influenza vaccine deltaFLU

differs from a conventional influenza vaccine in three major characteristics and in the method of production:

1. Nasal Spray

The vaccine is administered intranasally with a spray device instead of being injected into a muscle. This approach offers the major advantage of stimulating the v
'/>"/>

SOURCE Avir Green Hills Biotechnology Trade AG
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related medicine technology :

1. BN ImmunoTherapeutics Starts Clinical Trials With Prostate Cancer Vaccine
2. InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C
3. Impliant Restarts Pivotal Clinical Trial for Patented TOPS(TM) Spine System
4. TriLink Awarded a Phase II Grant for a Second Hot Start PCR Project
5. Starting Flu Vaccination in August Could Help Protect Nearly 11 Million More Children During Scheduled Doctors Visits
6. MedImmune Advances Asthma Program with Start of a Phase 2 Trial in Europe and Australia and First U.S.-Based Clinical Trial for Antibody Targeting IL-13
7. Diamyd(R) Diabetes Vaccine Receives Approval to Start Phase III Trials in Europe
8. VIDEO: Femara(R) helps protect against return of breast cancer even when treatment starts several years after completing tamoxifen therapy
9. Michael J. Fox Foundation Awards Up to $3 Million to Industry Teams to Jumpstart Promising PD Drug Development
10. Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
11. GlaxoSmithKline and Theravance Announce Start of Large Phase 2B ICS and LABA Studies for Asthma in the Horizon Program

Post Your Comments:

(Date:5/21/2013)... -- Concord Medical Services Holdings Limited ("Concord Medical" or ... specialty hospital management solution provider and operator of the ... China and the parent of Chang,an Hospital, today reported ... ended March 31, 2013 [1] . First ... consists of net revenues generated from the network business ...

(Date:5/21/2013)... FRANCISCO , May 21, 2013 ... of the American Psychiatric Association show that the ... and clinically meaningful response and remission in patients ... phase of therapy, which were maintained through one ... treatment, 62 percent of patients achieved symptomatic improvement ...

(Date:5/21/2013)... N.Y., May 21, 2013 Lakeland Industries, Inc. ... manufacturer of industrial protective clothing for industry, municipalities, ... and local levels, today announced that the Company ... a Senior Credit Facility subject to certain terms ... this financing. However, no assurances can be given ...

[0] Concord Medical Reports First Quarter 2013 Financial Results [0] New Data Show Long-Term Benefit of Transcranial Magnetic Stimulation in Difficult-to-Treat Patients with Depression using NeuroStar TMS Therapy System [0] Lakeland Industries, Inc. Reports Fiscal 2013 Fourth Quarter and Full Year Financial Results

... demonstrate favorable safety and tolerability profile, ROCKVILLE, ... VNDA ) announced today that data from four ... an investigational atypical,antipsychotic, is associated with significantly greater ... has a favorable safety and,tolerability profile. These results ...

... Mothers, to Protect Themselves and Their Families This ... and Every Year ... WHAT: Kristi Yamaguchi, Olympic Gold Medalist ... LaShell Griffin, Oprah,s Pop Star Challenge Winner, ...

Cached Medicine Technology:Vanda Presents Phase III Iloperidone Efficacy Data 2 Vanda Presents Phase III Iloperidone Efficacy Data 3 Vanda Presents Phase III Iloperidone Efficacy Data 4 Olympic Gold Medalist Kristi Yamaguchi Joins American Lung Association of Michigan to Address Seriously Low Vaccination Rates; Urge Metro-Detroiters to Get Immunized This Season 2 Olympic Gold Medalist Kristi Yamaguchi Joins American Lung Association of Michigan to Address Seriously Low Vaccination Rates; Urge Metro-Detroiters to Get Immunized This Season 3

Vanda Presents Phase III Iloperidone Efficacy Data Olympic Gold Medalist Kristi Yamaguchi Joins American Lung Association of Michigan to Address Seriously Low Vaccination Rates; Urge Metro-Detroiters to Get Immunized This Season

(Date:5/22/2013)... France: Results from a large observational study ... bivalirudin is superior to heparin in the ... mortality in patients with non-ST segment elevation ... intervention (PCI)., European and US NSTE-ACS guidelines ... to unfractionated heparin plus GP IIb/IIIa receptor ...

(Date:5/22/2013)... 2013 The PreDiabetes Center of ... the Greater Philadelphia Tour de Cure, a premier cycling event ... passionate about stopping the spread of diabetes , a ... , The Tour de Cure will take place Saturday, June ... in Ambler, 30 minutes outside of Philadelphia, between the hours ...

(Date:5/22/2013)... New York (PRWEB) May 22, 2013 According ... Culture, Consequences, and Cost ” article published recently at FinancesOnline.com ... fully justified. The Centers for Disease Control and Prevention ... aged 20 and over are overweight, 35.7% are obese, and ... highlighted in this investigative article. In particular, the article focuses ...

(Date:5/22/2013)... Georgia (PRWEB) May 22, 2013 ... finalists for its Better Play & Recreation Contest, ... hundreds of thousands of youth, people with disabilities, ... need of rescue. The general public is encouraged ... to help their favorite non-profit organization win the ...

(Date:5/22/2013)... City, NJ (PRWEB) May 22, 2013 ... compliance, and management solutions for social enterprise collaboration ... LLC, a consulting firm based in Chicago, Ill. ... integrate their products and provide best-in-class solutions for ... and improve collaboration. , AvePoint’s DocAve Software ...

Breaking Medicine News(10 mins):Health News:Registry questions superiority of bivalirudin over heparin 2 Health News:PreDiabetes Centers to Appear at the Philadelphia Tour de Cure 2 Health News:PreDiabetes Centers to Appear at the Philadelphia Tour de Cure 3 Health News:Black American Obesity Examined In The Latest FinancesOnline.com Article 2 Health News:Black American Obesity Examined In The Latest FinancesOnline.com Article 3 Health News:Public Voting Opens for Finalists in Synthetic Turf International’s Better Play & Recreation Contest 2 Health News:AvePoint Teams with Tahoe Partners, LLC to Enrich Microsoft SharePoint Deployments and Improve Collaboration 2 Health News:AvePoint Teams with Tahoe Partners, LLC to Enrich Microsoft SharePoint Deployments and Improve Collaboration 3

[0] Registry questions superiority of bivalirudin over heparin [0] PreDiabetes Centers to Appear at the Philadelphia Tour de Cure [0] Black American Obesity Examined In The Latest FinancesOnline.com Article [0] Public Voting Opens for Finalists in Synthetic Turf International’s Better Play & Recreation Contest [0] AvePoint Teams with Tahoe Partners, LLC to Enrich Microsoft SharePoint Deployments and Improve Collaboration

... intra-aortic balloon pumps prior to angioplasty in patients with ... of heart muscle damage, a condition referred to as ... Duke University Medical Center researchers. The findings ... the American Medical Association ( JAMA ), and ...

... , MONDAY, Aug. 29 (HealthDay News) -- Although older ... may not be making good decisions about their coverage, ... -- particularly those with impaired brain function -- can ... plans available to them, preventing them from finding the ...

... , MONDAY, Aug. 29 (HealthDay News) -- The width ... performs, according to a new study. Researchers compared the ... their companies, financial performance. The study included only men because ... behavior applies only to men. The firms of CEOs ...

... agree that financial constraints and an aging population will require ... find that pushing back the eligibility age could be a ... most. The consequences both positive and negative of ... presented in the latest installment of the Public Policy & ...

... Caution is required when deciding whether to stop life support ... Researchers examined death rates after life support was ... brain injury in six trauma centers in the Canadian provinces ... the patients died in hospital, but the rate varied from ...

... EMPHASIS-HF study showed significant reductions in death and hospitalization ... failure (CHF) and mild symptoms treated with eplerenone in ... and standard therapy. Commenting on the findings presented ... Cardiology Congress (ESC) Hot Line Session on 29th August ...

Cached Medicine News:Health News:Study shows balloon pump use prior to angioplasty does not reduce heart muscle damage 2 Health News:Some Older Americans Overwhelmed by Medicare Options, Study Says 2 Health News:Some Older Americans Overwhelmed by Medicare Options, Study Says 3 Health News:Aging authorities differ on tweaks to Social Security's benefit structure 2 Health News:Use Caution in Ending Life Support for Brain-Injured, Experts Say 2 Health News:The effect of eplerenone vs. placebo on cardiovascular mortality 2 Health News:The effect of eplerenone vs. placebo on cardiovascular mortality 3

Study shows balloon pump use prior to angioplasty does not reduce heart muscle damage Some Older Americans Overwhelmed by Medicare Options, Study Says Is Shape of CEO's Face a Measure of Power?Aging authorities differ on tweaks to Social Security's benefit structure Use Caution in Ending Life Support for Brain-Injured, Experts Say The effect of eplerenone vs. placebo on cardiovascular mortality

... wide range of Platelet aggregometers allows ... meet particular needs. Single, dual and ... chart recorder outputs or digital computer ... Optical aggregometers, which measure platelet aggregation ...

... The PAP-4C is a four channel platelet ... available: chromogenic assays, von Willebrand assay (Ristocetin ... PAP-4C may also be used for the ... (HIT). Four channels allow four tests to ...

Express Plus analyzer is a great choice for small and medium workloads....

Iron / TIBC (Ferrozine). Storage temp: 2 - 8 C. Linearity: 0 - 500 ug/dl. Expected values: from TIBC 250 - 400 ug/dl, from Iron 40 - 160 ug/dl. Available with Calibrator and Number of test are 100....

Medicine Products:

Series 400 Aggregometers PAP-4C Express Plus Iron / TIBC (Ferrozine)